NeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 22, 2016 09:43 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson’s Disease
December 22, 2016 07:00 ET
|
NeuroDerm Ltd.
- First evaluation of clinical efficacy of ND0612H in advanced Parkinson's patients -REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage...
NeuroDerm Announces Closing of a Follow-On Offering of Ordinary Shares
December 12, 2016 10:38 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 12, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Pricing of a Follow-On Offering of Ordinary Shares
December 07, 2016 08:50 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 07, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Launch of a Follow-On Offering of Ordinary Shares
December 06, 2016 16:14 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 06, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm to Replace Two Phase 3 Clinical Trials with Small Pharmacokinetic Trials Following FDA Meeting on ND0612 Regulatory Development
December 05, 2016 06:30 ET
|
NeuroDerm Ltd.
- Company to pursue comparative bioavailability regulatory route instead of clinical efficacy development route -- NeuroDerm to add patients to its long-term safety trial -- Conference call and...
NeuroDerm Announces Top-Line Results of Pilot PK Trial Comparing ND0701 with Commercial Apomorphine
December 02, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 02, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical Company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm Announces Third Quarter 2016 Financial Results
November 10, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 10, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm CEO to Present at Upcoming Investor Conferences
November 03, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 03, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm to Host Third Quarter 2016 Financial Results Conference Call on November 10, 2016
November 01, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...